Otovia Therapeutics

There are 466 million hearing-disabled
people in the world
32 million of which are in China
Patients' needs are our missio

Otovia is a biotech company focusing on innovative drugs for diseases related to inner ear hearing loss

About Otovia

Otovia, established in January 2022 by the Fosun Health Fund, is a biotech company focusing on innovative drugs for diseases related to inner ear hearing loss. It develops gene delivery, gene editing, and inner hair cell regeneration drugs for sensorineural deafness through five major platforms, including dual adeno-associated virus (AAV) gene delivery, gene editing and organoid, which have achieved international leadership.

Chief scientists

Technical team

Management team